Two Cases of Non-Small Cell Lung Cancer Masquerading as Metastatic Papillary Thyroid Cancer

2012 ◽  
Vol 5 (2) ◽  
pp. 157
Author(s):  
Ju Hee Lee ◽  
Se-Hoon Lee ◽  
Hye Sook Min ◽  
Ji-hoon Kim ◽  
Do Joon Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Papillary Thyroid Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Papillary Thyroid ◽  
Small Cell Lung

Metastatic Papillary Thyroid Cancer Misdiagnosed as Non-Small Cell Lung Cancer

Thyroid ◽  
2011 ◽  
Vol 21 (3) ◽  
pp. 319-323 ◽  
Author(s):  
Jacob Moalem ◽  
Daniel X. Choi ◽  
Elham Khanafshar ◽  
Daniel T. Ruan ◽  
Kenneth A. Woeber ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Papillary Thyroid Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Papillary Thyroid ◽  
Small Cell Lung

A contemporary review of rearranged during transfection-selective inhibitors

2021 ◽  
pp. 107815522110405
Author(s):  
Angel W Liu ◽  
Connie Liang ◽  
Chung-Shien Lee
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Objective Response ◽  
Small Cell ◽  
Suppressive Therapy ◽  
Selective Inhibitors ◽  
Small Cell Lung ◽  
Pivotal Phase

Objective Rearranged during transfection genes are present in 1−2% of patients who have non-small cell lung cancer and 10−30% of patients with papillary thyroid cancer. The objective of this article is to review the current rearranged during transfection inhibitors indicated for patients with rearranged during transfection-mutated cancers and their future directions. Data sources: The pivotal phase I/II studies for selpercatinib and pralsetinib were evaluated. Current studies on rearranged during transfection inhibitors were searched on ClinicalTrials.gov using the key word “RET.” Data summary: Selpercatinib and pralsetinib were the first two U.S. Food and Drug Administration-approved rearranged during transfection-selective inhibitors for advanced or metastatic rearranged during transfection fusion-positive non-small cell lung cancer, rearranged during transfection-mutant medullary thyroid cancer, and rearranged during transfection fusion-positive thyroid cancer. Both agents showed promising efficacy with objective response rate ranging from 60% to 73% in all aforementioned rearranged during transfection-mutated cancers. Additionally, benefits were seen even in patients with intracranial metastasis at baseline. Both showed favorable safety profiles. Some common class adverse events included elevated liver function tests and hypertension. Hematologic side effects such as anemia and neutropenia were more common with pralsetinib. Selpercatinib had interactions with acid suppressive therapy and specific instructions when used concomitantly. Conclusions While the rearranged during transfection inhibitors are generally well-tolerated, each agent possesses slightly different efficacy, side-effect profile, and drug−drug interactions.

scholarly journals Alteration of DNA mismatch repair capacity underlying the co-occurrence of non-small-cell lung cancer and nonmedullary thyroid cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shiro Fujita ◽  
Katsuhiro Masago
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Mismatch Repair ◽  
Cell Lung Cancer ◽  
Dna Mismatch Repair ◽  
Small Cell ◽  
Small Cell Lung ◽  
Repair Capacity ◽  
Dna Mismatch

AbstractBoth non-small-cell lung cancer cases in never-smokers and nonmedullary thyroid cancer cases have been increasing in developed countries. Some studies have shown an excess of co-occurrence of non-small-cell lung cancer and nonmedullary thyroid cancer. We aimed to clarify the underlying genetic factors that contribute to the occurrence of these two malignancies. We performed germline exome sequencing in a cohort of 9 patients with the two malignancies. In terms of candidate genes, we performed target resequencing, immunohistochemistry, and microsatellite instability testing on another cohort. Two rare missense heterozygous variants in MSH6 were identified and verified by Sanger sequencing. One available tumour specimen showed heterogeneous MSH6 status in immunohistochemistry. Further exploration with different cohorts (a total of 8 patients with the two malignancies) demonstrated that 2 out of 8 patients had a germline missense or promotor variant of MLH1 and four out of 10 tumour specimens revealed heterogeneous immunohistochemistry staining in any of the four mismatch repair proteins: MLH1, PMS2, MSH2 and MSH6. Although our cohort showed a different disease profile than Lynch syndrome, this study suggests causal roles of impaired DNA mismatch repair capacity in non-small-cell lung cancer and nonmedullary thyroid cancer.

Sign in / Sign up

Export Citation Format

Share Document